SOURCE: Napoli Shkolnik PLLC

Napoli Shkolnik PLLC

May 19, 2016 11:43 ET

Drug Safety Communication Alert

NEW YORK, NY--(Marketwired - May 19, 2016) - Napoli Shkolnik PLLC has learned that the Federal Drug Administration (FDA) has issued an alert for the patients of diabetes drugs Invokana and Invokamet.

As part of ongoing clinical trials, the interim safety results have found an increase in leg and foot amputations, mostly affecting the toes, in patients being treated with the diabetes medication Invokana and Invokamet.

In addition, users of these diabetes drugs have also experienced other serious side effects such as kidney failure, heart attack and the health condition known as ketoacidosis, which causes diabetic comas or death. Current lawsuits allege that the manufacturer failed to properly warn patients of the potential increased risks associated with taking Invokana and Invokamet.

These possible health risks are obviously serious and we encourage patients of these adult type II diabetes drugs to contact us immediately if they are experiencing the above described complications.

About the firm

Napoli Shkolnik PLLC is a national litigation firm providing representation to victims of defective prescriptions drugs and medical devices, asbestos-related illnesses, environmental contamination disasters, aviation accidents, complex litigation and other serious personal injury matters. With their principal offices in New York City and additional offices in California, Delaware, Florida, Illinois, New Jersey, Pennsylvania, Texas and affiliates through the United States, Napoli Shkolnik PLLC is readily available to clients.

Contact Information

  • Contact Information: 
    Hunter J. Shkolnik, Esq.
    Napoli Shkolnik PLLC
    360 Lexington Avenue, 11th Floor
    New York, NY 10017
    (212) 397-1000